Kurin, Inc. Receives Supplier Horizon Award from Premier Inc.

/in

Kurin today announced that it is a winner of the Supplier Horizon Award from Premier Inc., a leading healthcare improvement company.

One of nine suppliers to receive the award this year, Kurin was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.

“We are honored to be recognized by Premier for this Horizon Award,” said Bob Rogers, CEO of Kurin, Inc. “We are pleased that Kurin was acknowledged for the value we are bringing to Premier hospitals and for sharing in their pursuit of clinical excellence. Premier hospitals have reported significant reductions in blood culture contaminations with Kurin and we look forward to continuing to expand our relationship with this great organization.”

Horizon Award winners have a tenure of fewer than three years as a Premier contracted supplier.

“Kurin supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier. “We’re honored to recognize them as a Horizon Award recipient.”

About Premier Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and health systems and approximately 200,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. continues sales growth with record month.

/in

Kurin Inc., announced record monthly sales of the Kurin Lock®, its revolutionary passive discard device that helps hospitals reduce contaminated blood cultures. July brought continued acceleration in Kurin sales and the company noted the importance of blood culture tests during the current pandemic. Although accurate testing is always important for the patient and the financial health of the hospital, optimally diagnosing bloodstream infections in highly vulnerable COVID patients is even more critical.

“Kurin has been instrumental for many hospitals in their efforts to provide excellent healthcare, especially in these trying times,” said Bob Rogers, CEO of Kurin. “We started this business to make a difference in healthcare and it is rewarding to see the belief that so many hospitals have in Kurin, as evidenced by our record sales.”

Kurin also addressed a recent court decision in one of Kurin’s false advertising suits against Magnolia Medical. In dismissing Kurin’s legal claims, the Court found that certain statements made by Magnolia regarding the efficacy of its Steripath product were “literally false,” and determined that various other Magnolia product claims are “puffery,” which the Court defined as “exaggerated advertising, blustering, and boasting.”

“While we are disappointed in the recent ruling and believe that the Court did not properly consider certain issues and evidence, Kurin initiated this lawsuit to address Magnolia’s use of false and misleading statements regarding both the efficacy and FDA status of its products.  As a result of the litigation, Magnolia has recently corrected their years of past misbehavior of selling without the necessary FDA clearances by seeking and finally receiving the FDA’s 510(k) clearance to market their Steripath products, modified its advertising, and provided important context for many of its product claims. In this respect, Kurin’s primary objective of establishing a more level playing field has been largely achieved. We believe there is a responsibility in the medical industry to maintain a high standard of integrity and feel the Court’s opinion, in fact, supports the merits of our false advertising lawsuit,” said Mr. Rogers.

“The more important lawsuit between our two companies is the patent lawsuit that is in process, and we remain very confident in prevailing in that matter,” said Mr. Rogers. “In the meantime, our focus remains on helping hospitals and we are pleased that hospitals continue to select Kurin over Steripath when directly competing. Dozens of hospitals that had used Steripath are now using Kurin, opting for a simpler, smaller, user-friendly, and more cost-effective solution to their contaminated blood culture problem.”

Kurin offers an initial specimen discard technology that automatically and passively sidelines potential contaminants during blood culture collection. When skin microbes enter into blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment and risk for patients and significant costs for the hospital.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Agreement with Intalere for Kurin Lock to impact contaminated blood cultures

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that it has been awarded a contract by Intalere for the Kurin product line. Effective July 1, 2020 the new three-year agreement allows Intalere members to take advantage of special pricing and terms.

“An agreement with Intalere is another important accomplishment for Kurin,” said Bob Rogers, Inventor and CEO of Kurin. “Hospitals are under increasing pressure to quickly and accurately diagnose their patients. Intalere emphasizes best practices and patient outcomes and we share patient safety values by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing so, reducing overall healthcare costs.”

Kurin’s revolutionary and disruptive approach automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as approximately one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection. Contaminated blood cultures also create a financial burden to hospitals by prolonging hospital stays.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Agreement with Vizient for Kurin Lock to help reduce contaminated blood cultures

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that it has been awarded a contract for the Kurin Lock®, a blood culture optimization device designed to reduce contamination rates. Effective April 1, 2020, the new agreement offers Vizient members negotiated pricing and terms.

“We are pleased to have this agreement with Vizient,” said Bob Rogers, Inventor and CEO of Kurin. “Several Vizient member hospitals have already benefitted from sustained results in reducing their blood culture contamination rates with Kurin and formalizing this agreement will help additional hospitals add Kurin to their important work in protecting patients from harm. By providing this innovative solution at contracted pricing, Vizient and Kurin are helping to reduce overall healthcare costs.”

Kurin’s revolutionary and disruptive approach automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection. Contaminated blood cultures also create a financial burden to hospitals by prolonging hospital stays.

Vizient is the largest member-driven performance improvement company in the country. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. receives FDA 510k clearance for its push-button needle

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received 510(k) clearance (k191832) for its novel push-button needle.

“The FDA clearance of our push-button needle is another important step in the continued growth of our company,” said Bob Rogers, CEO of Kurin. “Development of our proprietary needle provides us vertical integration and also allows us to offer superior options to our customers. We are experiencing exponential growth and milestones like this one position Kurin well for our rapid expansion plans,” said Mr. Rogers.

Kurin developed initial specimen discard technology that automatically and passively sidelines potential contaminants during blood culture collection. When skin microbes enter into blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment and risk for patients, as well as significant costs for the hospital. Kurin’s patented automatic blood discard product is the only FDA 510(k) cleared blood culture product in its class.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Hire of EVP Operations Amid Record Growth

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared and patented Kurin® blood culture collection sets announced the hiring of Don Canal to the newly created position of Executive Vice President, Operations. 

“Bringing Mr. Canal into Kurin is an important addition to our company,” said Bob Rogers, CEO of Kurin, Inc. “Demand for Kurin’s products is growing at a torrid rate. The addition of Mr. Canal demonstrates our commitment to excellence. Mr. Canal’s extensive medical device manufacturing, operations, and regulatory experience, including most recently our work together at Ivera Medical, builds on our ability to handle the rapidly increasing demand for Kurin.”                                                

Kurin’s Initial Specimen Discard (KISD) technology is superior to currently marketed diversion technologies, requiring no user interaction with complicated manual manipulations. The Kurin Lock® automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Third Quarter Revenues

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared and patented Kurin® blood culture collection sets announced third quarter revenues increased 4.5 times over the revenue of the same period in 2018. Kurin also reports third quarter sales exceeded their total revenues for 2018.

“We want to thank our customers for their support and trust in Kurin. These forward thinking, quality driven organizations saw the value of Kurin, clinically, financially, and as part of the important fight against growing antimicrobial resistance. Since the close of 2018, we have seen strong sequential quarter over quarter growth,” said Bob Rogers, CEO of Kurin, Inc. “Kurin’s elegantly simple, intuitive design requires no additional user steps. Kurin coupled with adherence to policy is helping customers to achieve higher compliance and delivering significant reductions in false positive blood cultures. Our customer results combined with an extraordinary team of people are driving our success.”

Kurin’s revolutionary and disruptive approach to the initial specimen diversion technique, automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. receives CE Mark for its novel Kurin Lock®

/in

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received its CE Mark that allows product distribution into the European Economic Area (EEA) and European Union (EU) Candidate Member States (i.e. Iceland and Turkey).

“We are pleased to receive the CE Mark, the clearance needed for medical products to be marketed in this important region,” said Bob Rogers, CEO of Kurin. “The family of Kurin products was developed to help hospitals improve their blood culture samples and we look forward to helping hospitals in the EEA and EU Candidate States in their efforts to lower their contamination rates.”

Kurin developed initial specimen diversion technology that automatically and passively diverts potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

Kurin’s patented automatic blood diversion product is the only FDA 510k-cleared blood culture diversion product in the US and now holds that same distinction for the European market.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin Inc. Responds to Allegations Published by Magnolia Medical Regarding Patent Infringement

/in

Kurin Inc., manufacturer of Kurin® blood culture collection sets, responds to comments made by Greg Bullington, CEO of Magnolia Medical, in a letter Magnolia published regarding their patent-infringement lawsuit against Kurin.

“Magnolia’s unusual tactic to email blast their allegations of patent infringement has created confusion for healthcare providers, and we are compelled to address this action,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock®. “Kurin reassures our customers and potential customers that these allegations are false. Kurin is here solely to serve our customers, and we will continue to do so with disruptive technological innovations like the elegantly simple, FDA 510(k) cleared, Kurin Lock. In contrast, Magnolia Medical could be a study on mismanagement. Steripath has been on the market for years, but its poor design makes it bulky, awkward, and difficult to operate. Their response to address these product deficiencies was to launch virtually the same device: Steripath Gen. 2.”

Continuing Rogers said, “Magnolia has engaged in a pattern of deception, marketing a device it claims does not require FDA 510(k) clearance (Kurin has been issued two 510(k) clearances), and misleading customers with selective use of clinical performance data. Since we launched the Kurin Lock, Magnolia has continuously told customers that Kurin does not work. Magnolia, now desperate, really wants everyone to believe that they invented the Kurin Lock! If this were true, Magnolia would never have chosen its Rube Goldberg Steripath design.”

“When you compare the two devices it is clear, the Kurin Lock is unrelated to anything Magnolia ever conceived. In fact, the U.S. Patent Office has repeatedly found the design of the Kurin Lock to be novel compared to Magnolia’s patents, and has already issued three patents on the Kurin Lock concept,” said Mr. Rogers. “The Kurin Lock does not infringe any Magnolia patent and we are confident that this position will be proven in court.”

“In closing,” said Rogers, “we are quite familiar with this situation. At our last company, Ivera Medical, makers of the green Curos Port Protector, we prevailed over a host of similar patent related attacks. As with Curos, the Kurin Lock is, and will remain, on the market throughout this process, as long as it takes.”

About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. CEO Addresses Patent Infringement Lawsuit Brought by Magnolia Medical

/in

We have had interested parties asking for clarification regarding the patent infringement case Magnolia has filed against Kurin. The short answer is: we are very comfortable with our position and, if the concern is regarding Kurin and its availability in your facilities, you should have no concerns.

First, the timing of the suit is not a coincidence. For the first year, Magnolia harshly attacked the Kurin Lock design, claiming that the diversion volume was too low to reduce contaminations and that because the Kurin Lock does not completely isolate blood it cannot work. With our continued clinical success these arguments have been proven false, and now they are undermining Magnolia’s reputation. Several Steripath hospitals, across the country, have recently switched to Kurin because they are getting the same or better clinical results and clinicians are much happier with the simplicity of Kurin. Unable to compete successfully in the market, Magnolia has turned to desperate allegations of patent infringement.

At Kurin, we respect the intellectual property rights of others. This is apparent in the design of the Kurin Lock, which is fundamentally different from Steripath in concept and operation, and which Magnolia previously claimed would not work.  The groundbreaking design of the Kurin Lock has itself been found novel compared to Magnolia’s patents and worthy of its own patent protection by the U.S. Patent Office. We firmly believe that the Kurin Lock does not infringe any Magnolia patent, and we remain confident that this position will be proven out in the courts.

Our team at Kurin has a great deal of patent litigation experience. At our last company, Ivera Medical (the Curos green cap designed to decrease bloodstream infections) we created a whole new class of medical devices and with our success many tried to copy us. We were involved in multiple infringement cases (both on offense and defense) and when the dust settled, we prevailed. We understand patent litigation and how to manage it, and we are confident that our patent team will serve us as well with Kurin as they did with Curos.

Based on our experience, we expect this case to take years to work through the system and candidly, it will cost a lot of money. With the good fortune of selling our last company, we have plenty of financial resources to follow this case through to the end. We see no impact on product availability, during or after the case, so please take comfort in that. If there is further information you need, please let me know and I will do what I can to help.

Bob Rogers,
CEO, Kurin, Inc.
bobrogers@kurin.com